A Brain Cancer Drug Has Been Waiting 931 Days for FDA Review

Northwest Biotherapeutics submitted its brain cancer treatment DCVax-L to the FDA over two and a half years ago and is still waiting for a regulatory decision. The prolonged review raises serious questions about FDA timelines, capacity, and what happens to patients with no other options in the meantime.

Why it matters

DCVax-L is a personalized dendritic cell immunotherapy developed by Northwest Biotherapeutics for glioblastoma, a cancer where median survival is measured in months and meaningful treatment advances have been rare. The company submitted its application to the FDA more than two and a half years ago. As of this writing, no decision has been issued.

The length of this review is worth examining carefully. FDA review timelines exist for good reasons, and complexity in the evidence base can legitimately slow a decision. But 931 days with no clear public explanation stretches past the threshold of reasonable. For patients with glioblastoma, that timeline is not abstract. It represents a treatment window that may have already closed for many of them.

What to watch

Whether the FDA issues a formal response or action date, and whether Congressional or advocacy pressure accelerates the timeline for this and similar stalled oncology applications.